Department of Hematology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Adult Clinical Hematology and Bone Marrow Transplantation Unit, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Int J Lab Hematol. 2022 Feb;44(1):157-162. doi: 10.1111/ijlh.13731. Epub 2021 Oct 11.
Immunomagnetic cell sorting (IMCS) is a preferred technique for the enrichment of plasma cells (PC) before fluorescence in situ hybridization (FISH). Here, we share our real-world experience regarding the success rate of IMCS, its limitations, and the utility of alternate sources to obtain a successful FISH in various PC disorders.
A retrospective analysis was performed in patients with a PC neoplasm, who underwent bone marrow (BM) examination, and FISH testing over 30 months. In all cases with an unsuccessful IMCS, an attempt was made to identify the cause of failure.
Immunomagnetic cell sorting of PCs was successful in 395/450 cases (87.8%; 77/98 cases (78.6%) with <10% PCs and 318/352 (90.3%) with ≥10% PCs in BM aspirate; P = .003). Among cases with unsuccessful IMCS (<10% PCs; n = 21 and ≥10% PCs; n = 34), an alternate source could be used successfully in 34 (62%) patients and includes air-dried trephine biopsy imprint smears (n = 28) with aggregates or sheets of PCs, fine-needle aspiration smears/biopsy from plasmacytoma (n = 5), and ascitic fluid (n = 1). 284/395 (71.9%) patients with successful IMCS and all 34 cases with an alternate source of PCs showed at least one cytogenetic abnormality on four-probe FISH.
Variations in the sample quality together with significant variation in the number of PCs between BM aspirate and the trephine biopsy imprint smears/biopsy reduce the success rate of IMCS in a real-world scenario and necessitate utilization of patient-specific alternate sources of PCs like a trephine biopsy imprint or cytology smears from extramedullary sources for successful FISH testing in PC neoplasms.
免疫磁珠细胞分选(IMCS)是荧光原位杂交(FISH)前富集浆细胞(PC)的首选技术。在这里,我们分享在各种 PC 疾病中,我们在实际应用中获得的关于 IMCS 成功率、其局限性以及获得成功 FISH 的替代来源的经验。
对 30 个月内接受骨髓(BM)检查和 FISH 检测的 PC 肿瘤患者进行回顾性分析。在所有 IMCS 不成功的病例中,都试图确定失败的原因。
395/450 例(87.8%;77/98 例(78.6%)BM 抽吸物中 PC 计数<10%,318/352 例(90.3%)PC 计数≥10%)的 PC 免疫磁珠分选成功。在 IMCS 不成功的病例中(<10% PCs;n=21 和≥10% PCs;n=34),34 例(62%)患者可以成功使用替代来源,包括空气干燥的钻取活检印片中有 PC 聚集或成层的涂片(n=28)、浆细胞瘤的细针抽吸涂片/活检(n=5)和腹水(n=1)。284/395 例(71.9%)成功进行 IMCS 的患者和所有 34 例具有替代 PC 来源的患者在四探针 FISH 上均显示至少一种细胞遗传学异常。
在实际情况下,样本质量的变化以及 BM 抽吸物和钻取活检印片/活检中的 PC 数量之间存在显著差异,降低了 IMCS 的成功率,需要针对特定患者使用替代来源的 PC,如钻取活检印片或来自髓外部位的细胞学涂片,以便在 PC 肿瘤中成功进行 FISH 检测。